Home > Infinity Pharmaceuticals Salary

Infinity Pharmaceuticals Salary

  • 27
  • 25
  • 25
Infinity Pharmaceuticals average salary is $66,547, median salary is $64,400 with a salary range from $64,400 to $70,840.
Infinity Pharmaceuticals salaries are collected from government agencies and companies. Each salary is associated with a real job position. Infinity Pharmaceuticals salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Total 3 Infinity Pharmaceuticals Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Software Engineer 70,840-70,840 Cornelia, GA, 30531 2013 Infinity Pharmaceuticals Software Engineer Salaries (3)
Infinity Pharmaceuticals Cornelia, GA Salaries
Software Engineer 64,400-64,400 Baldwin, GA, 30511 2010 Infinity Pharmaceuticals Software Engineer Salaries (3)
Infinity Pharmaceuticals Baldwin, GA Salaries
Software Engineer 64,400-64,400 Cornelia, GA, 30531 2010 Infinity Pharmaceuticals Software Engineer Salaries (3)
Infinity Pharmaceuticals Cornelia, GA Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Infinity Pharmaceuticals salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Infinity Pharmaceuticals Jobs
See more Infinity Pharmaceuticals Jobs»
Search All Jobs

JobsOpenHiring – Find open jobs faster
Infinity Pharmaceutica... Information
  • Infinity Pharmaceuticals Inc
  • Industry: BioTech/Drugs
  • City: Cambridge, MA
  • Infinity Pharmaceuticals, Inc. (IPI) has developed a pipeline of product candidates for multiple cancer indications. The Company¡¯s lead product candidate, retaspimycin hydrochloride (IPI-504) is an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90). Hsp90 is a central component of the cellular chaperone system, which supports and stabilizes cancer-causing proteins, such as c-Kit, EGFR, and HER2, enabling multiple forms of cancer to thrive. Inhibition of the Hsp90 chaperone knocks out this critical source of support for cancer cells, leading to tumor growth inhibition and cancer cell death. In October 2008, the commenced an international Phase III registration study of